LCN2 and subarachnoid hemorrhage: Besides, LCN2 has been demonstrated as a biomarker for inflammatory bowel disease (Thorsvik et al., 2017), vascular dementia (Llorens et al., 2020), neuropsychiatric lupus (Mike et al., 2019), and subarachnoid hemorrhage outcome (Yu et al., 2021).